Cleara Biotech
Cleara is developing therapeutics to eliminate senescent cells.
Cleara Biotech discovered a mechanism that shows how senescent cells escape the natural elimination process. Based on this discovery, Cleara is developing therapeutics to treat patients with a range of diseases caused by this failure to clear senescent cells.
Visit website: https://www.clearabiotech.com/
Login to view link, or join the club to get full access to all resources and other benefits.
Login to view link, or join the club to get full access to all resources and other benefits.
Cleara Biotech News
LMC provides background and success outlook on 14 leading senolytic companies
Longevity Marketcap - 15-Dec-2020
Comprehensive review of companies' clinical and financial state of play
Read more...Nature Biotechnology reviews the state of play of senolytics
Nature Biotechnology - 12-Nov-2020
In August, Unity announced that its lead drug candidate had failed to beat a placebo in reducing ...
Read more...Labiotech gathers feedback from European biotechs on Unity failure
Labiotech - 28-Aug-2020
General feeling that failures are bound to happen - but that their approaches can succeed
Read more...LEAF report from the Longevity Leaders Conference
Lifespan.io (LEAF) - 06-Feb-2019
Encouraging signs from big companies - more interviews to follow
Read more...Cleara Biotech Joins the Race to Develop Senolytic Therapies
Lifespan.io (LEAF) - 09-Jul-2018
This therapy uses a modified FOXO4 to promote apoptosis in senescent cells
Read more...
